Aurinia Pharmaceuticals
AUPH
25 hedge funds and large institutions have $18.1M invested in Aurinia Pharmaceuticals in 2016 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 4 closing their positions.
250% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 4
73% more call options, than puts
Call options by funds: $1.48M | Put options by funds: $856K
67% more funds holding
Funds holding: 15 → 25 (+10)
41% more capital invested
Capital invested by funds: $12.8M → $18.1M (+$5.31M)
25% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 4
21.72% more ownership
Funds ownership: 0% → 21.72% (+22%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NMC
NEA Management Company
Timonium,
Maryland
|
+$4.89M |
| 2 |
ACP
Acuta Capital Partners
Redwood City,
California
|
+$3.22M |
| 3 |
Goldman Sachs
New York
|
+$2.89M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$2.88M |
| 5 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$1.25M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
A
Abingworth
London,
United Kingdom
|
-$1.38M |
| 2 |
RG
Redmile Group
San Francisco,
California
|
-$485K |
| 3 |
Renaissance Technologies
New York
|
-$256K |
| 4 |
Creative Planning
Overland Park,
Kansas
|
-$190K |
| 5 |
VKH
Virtu KCG Holdings
New York
|
-$124K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Citadel Advisors
Miami,
Florida
| – | -$46K | -15,236 | Closed |
|
27
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
| – | -$206 | -64 | -94% |
|
28
Bank of America
Charlotte,
North Carolina
| – | +$322 | +100 | New |
|
|
RFA
29
Reilly Financial Advisors
La Mesa,
California
| – | +$322 | +100 | New |
|
AUPH Hedge Fund Activity: Q4 2016 in Review
25 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Aurinia Pharmaceuticals (AUPH) for Q4 2016, worth a combined $18.1M — up 41% from $12.8M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new AUPH positions and 4 closed out — a net gain of 10 holders — while 5 added to existing stakes and 4 trimmed.
The largest buyer was NEA Management Company, adding an estimated $4.89M. The largest seller was Abingworth, exiting entirely with an estimated $1.38M sold.
- 25 institutional investors held Aurinia Pharmaceuticals (AUPH) as of Q4 2016, up from 15 in Q3 2016.
- Funds reported $18.1M of Aurinia Pharmaceuticals stock for Q4 2016, up 41% quarter-over-quarter.
- 14 funds opened new Aurinia Pharmaceuticals positions in Q4 2016 and 4 closed out, a net change of +10 holders.
- The largest Aurinia Pharmaceuticals buyer in Q4 2016 was NEA Management Company, an estimated $4.89M added.
- The largest Aurinia Pharmaceuticals seller in Q4 2016 was Abingworth, an estimated $1.38M sold.
Based on aggregated 13F filings for Q4 2016.